Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
150%(6 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_4
1
17%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (33.3%)
Phase 33 (50.0%)
Phase 41 (16.7%)

Trials by Status

terminated233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_4

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
completedphase_3

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01310777
completedphase_2

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

NCT01426867
terminatedphase_2

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

NCT00961649
completedphase_3

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

NCT01297920
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02730871Phase 4

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Terminated
NCT01310777Phase 3

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Completed
NCT01426867Phase 2

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

Completed
NCT00961649Phase 2

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Terminated
NCT01297920Phase 3

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Completed
NCT01297517Phase 3

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6